Clearside Biomedical (CLSD) to Release Quarterly Earnings on Thursday

Clearside Biomedical (NASDAQ:CLSD) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Clearside Biomedical to post earnings of ($0.14) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The firm had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $3.40 million. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Stock Performance

Shares of Clearside Biomedical stock opened at $1.28 on Wednesday. The firm has a market capitalization of $95.64 million, a PE ratio of -2.42 and a beta of 2.35. Clearside Biomedical has a 12 month low of $0.65 and a 12 month high of $2.12. The business’s 50-day moving average price is $1.45 and its 200-day moving average price is $1.25.

Wall Street Analyst Weigh In

CLSD has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and issued a $4.00 price target (down from $5.00) on shares of Clearside Biomedical in a research note on Wednesday, March 13th. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Thursday, March 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Clearside Biomedical in a research note on Wednesday, March 13th. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Clearside Biomedical in a research report on Thursday, April 11th. Finally, StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $4.75.

Insider Buying and Selling

In other Clearside Biomedical news, insider Ngai Hang Victor Chong purchased 30,000 shares of the stock in a transaction on Wednesday, March 20th. The stock was acquired at an average price of $1.60 per share, with a total value of $48,000.00. Following the transaction, the insider now directly owns 30,000 shares of the company’s stock, valued at approximately $48,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.80% of the stock is owned by insiders.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.